JAZZ Biopharma · Rare disease · Neuroscience · Oncology · Thesis updated July 15, 2026

Xywav holds, but sleep pressure is rising

Xywav added 425 net patients in Q1 2026, reaching about 16,600 active patients.
Q1 2026 product sales rose 22% to $1.025 billion, helped by sleep, epilepsy, and oncology growth.
Epidiolex reached $1.1 billion in 2025 revenue, and generic risk is pushed into the very late 2030s.
Oncology is becoming more important, with Zepzelca, Modeyso, and Ziihera all contributing in Q1 2026.
The main worry is narcolepsy competition, including high-sodium generics and better-funded Lumryz.

01 Running thesis

The Xyrem handoff is working, for now

Jazz is trying to move past its old Xyrem franchise without losing the cash it needs to fund the next chapter. The early sign is good. Xywav, its lower-sodium oxybate drug, added 425 net patients in Q1 2026 and reached about 16,600 active patients, even after new high-sodium generics started to arrive.

The bull case is that Jazz can keep most valuable sleep patients on Xywav while Epidiolex keeps growing and oncology becomes a larger second engine. Zepzelca now has a first-line maintenance role in small cell lung cancer, and the FDA set an August 25, 2026 decision date for Ziihera in first-line gastroesophageal adenocarcinoma, a stomach and esophagus cancer market.

The bear case is that the sleep market could change fast in the second half of 2026. High-sodium generics may gain more volume. Lumryz has stronger backing after Alkermes bought Avadel. New wake-promoting drugs could also enter narcolepsy. If payers use cheaper choices to pressure Xywav, Jazz could lose price or patient share.

Finn's score sits in the middle because the business is performing well, but the story still depends on a hard handoff. Jazz must defend Xywav, grow Epidiolex, and prove the oncology pipeline can matter enough to offset sleep risk.

May 2026▲Q1 2026 showed better near-term Xywav resilience than feared, with 425 net patient adds and about 16,600 active patients. Jazz also confirmed an August 25, 2026 FDA decision date for Ziihera in first-line gastroesophageal adenocarcinoma.

Feb 2026▼Sleep competition became a larger risk. Amneal and Ascent had approvals for generic high-sodium oxybate, Alkermes bought Avadel and strengthened Lumryz, and Tris filed an application referencing Xyrem and Xywav.

Feb 2026→Epidiolex reached $1.1 billion of 2025 revenue, and Jazz settled ANDA litigation that moved generic risk into the very late 2030s. That support was partly offset by stopping the JZP441 orexin program.

Nov 2025▲Jazz cleared several overhangs and added oncology momentum. Modeyso was approved in August 2025, Zepzelca gained first-line maintenance approval in October 2025, and Xyrem antitrust and Avadel litigation were settled.

Aug 2025▼Macro reimbursement risk increased after H.R.1 was signed into law on July 4, 2025. Jazz warned that lower Medicaid spending could reduce access and reimbursement for its products.

02 Business model

Rare drugs, concentrated markets

Jazz makes money by selling branded medicines for rare or hard-to-treat diseases. These are not mass-market drugs. They are aimed at specific groups of doctors and patients, which can make the sales model efficient when the drug has a strong label and good insurance coverage.

Sleep is still the biggest source of product sales. In Q1 2026, Sleep product sales were $439.4 million, led by Xywav at $408.2 million. Xywav has 92% less sodium than Xyrem, which gives Jazz a clear medical message against high-sodium oxybate drugs.

Epilepsy adds a more durable base. Epidiolex and Epidyolex had $249.8 million of Q1 2026 product sales, and management said 2025 revenue reached $1.1 billion. Settlements moved expected U.S. generic entry into the very late 2030s, which gives Jazz more time to grow the product.

Oncology is the swing factor. Q1 2026 Oncology product sales were $333.4 million, up 45% from the prior year. That growth helps, but cancer drugs can rise or fall quickly based on trial data, FDA decisions, and rival launches.

03 Product portfolio

The drugs that drive the story

Cash cow

Xywav

Xywav is the key sleep drug and the main bridge away from Xyrem. It had $408.2 million of Q1 2026 product sales and about 16,600 active patients exiting the quarter.

Growth engine

Epidiolex and Epidyolex

This cannabidiol medicine treats seizures tied to rare epilepsies. It reached $1.1 billion of revenue in 2025 and grew 15% year over year in Q1 2026 product sales.

Growth engine

Zepzelca

Zepzelca treats small cell lung cancer. Q1 2026 sales were $101.0 million, helped by adoption in first-line maintenance after FDA approval in October 2025.

Steady

Rylaze and Enrylaze

Rylaze is used in certain leukemia and lymphoma patients who cannot use E. coli-derived asparaginase. Q1 2026 sales were $103.7 million, up 10% from the prior year.

Option

Ziihera

Ziihera is a HER2-directed cancer antibody. It launched in late 2024 for biliary tract cancer, and the next major event is the August 25, 2026 FDA decision date in first-line gastroesophageal adenocarcinoma.

Option

Modeyso

Modeyso is approved for a rare H3 K27M-mutant diffuse glioma brain tumor. It produced $41.4 million of Q1 2026 product sales, and the ACTION trial readout is expected in late 2026 or early 2027.

04 Business segments

Q1 sales mix

Sleep43%modest

Epilepsy24%modest

Oncology32%growing fast

Other product sales0%declining

The mix uses Q1 2026 product sales from Jazz's latest 10-Q. Sleep is still the largest area, so generic and payer pressure there can move the whole company.

05 Risk factors

What could break the thesis

Xywav payer pressure

High impact · High odds

Amneal and Ascent began dispensing generic high-sodium oxybate products in March 2026. Cheaper generics can push insurers to demand larger rebates or make patients try another drug first. That would hurt Xywav price, volume, or both.

We watchTrack Xywav active patients, Xywav net sales growth, and management comments on formulary access in H2 2026.

Stronger branded narcolepsy rivals

High impact · Medium odds

Lumryz is a branded high-sodium oxybate competitor, and Alkermes gained it when it acquired Avadel in February 2026. Jazz also expects possible new wake-promoting agents in the narcolepsy market in H2 2026. These drugs could reduce new Xywav starts or raise marketing costs.

We watchWatch Lumryz share updates, launch timing for new wake-promoting drugs, and Xywav narcolepsy patient adds.

Xywav patent challenge

High impact · Medium odds

In January 2026, Tris Pharma filed a Section 505(b)(2) application that references both Xyrem and Xywav. That creates a direct legal risk for the newer low-sodium franchise, not only the old high-sodium product. A bad ruling could pull forward competition.

We watchFollow the Tris litigation docket and any settlement terms tied to Xywav entry timing.

Oncology launch miss

Medium impact · Medium odds

Jazz needs oncology to become a bigger growth engine. Zepzelca faces pressure in second-line small cell lung cancer from Imdelltra, while Ziihera and Modeyso still need stronger data and broader use to matter at scale. If new labels or trial readouts disappoint, diversification slows.

We watchWatch Zepzelca first-line maintenance sales, the August 25, 2026 Ziihera FDA action date, and the Modeyso ACTION overall survival readout.

Government drug pricing pressure

Medium impact · Medium odds

U.S. health policy is becoming less friendly for drug makers. The H.R.1 budget bill is expected to reduce Medicaid spending, and potential Most-Favored Nation pricing rules could cut prices by tying U.S. prices to lower prices abroad. Rylaze and Epidiolex have higher government exposure, making them more sensitive to this risk.

We watchMonitor Medicaid access changes, Medicare pricing rules, and Jazz commentary on gross-to-net deductions.

06 Quick answers

In one breath

What does Jazz Pharmaceuticals make?

Jazz sells medicines for sleep disorders, rare epilepsies, and cancers. Its most important drugs include Xywav, Epidiolex, Rylaze, Zepzelca, Ziihera, and Modeyso.

Why is Xywav so important to Jazz?

Xywav is the lower-sodium follow-on to Xyrem and is Jazz's biggest product. It had $408.2 million of Q1 2026 product sales, so its patient count and insurance access are central to the stock story.

What is the next big catalyst for Jazz?

The FDA decision date for Ziihera in first-line gastroesophageal adenocarcinoma is August 25, 2026. Jazz also expects top-line overall survival data from the Modeyso ACTION trial in late 2026 or early 2027.

Is Jazz mainly a sleep company or an oncology company?

Today it is still heavily tied to sleep, but oncology is growing faster. In Q1 2026, Sleep product sales were $439.4 million and Oncology product sales were $333.4 million.